DZ2268A1 - Pyridines substituées comme inhibiteurs sélectifs de 2-cycloxygènase. - Google Patents

Pyridines substituées comme inhibiteurs sélectifs de 2-cycloxygènase.

Info

Publication number: DZ2268A1
Authority: DZ; Algeria
Prior art keywords: selective; substituted pyridines; cycloxygenase inhibitors; cycloxygenase; inhibitors
Prior art date: 1996-07-18

Application number

DZ970118A

Other languages

English (en)

Original Assignee

Merck Frosst Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-18

Filing date

1997-07-16

Publication date

2002-12-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ2268(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-08-01 Priority claimed from GBGB9616126.0A external-priority patent/GB9616126D0/en

1996-10-15 Priority claimed from GBGB9621420.0A external-priority patent/GB9621420D0/en

1997-05-07 Priority claimed from GBGB9709291.0A external-priority patent/GB9709291D0/en

1997-07-16 Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc

2002-12-25 Application granted granted Critical

2002-12-25 Publication of DZ2268A1 publication Critical patent/DZ2268A1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
- C07D213/34—Sulfur atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Neurology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Reproductive Health (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Oncology (AREA)
Dermatology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)

DZ970118A 1996-07-18 1997-07-16 Pyridines substituées comme inhibiteurs sélectifs de 2-cycloxygènase. DZ2268A1 (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US2212896P	1996-07-18	1996-07-18
GBGB9616126.0A GB9616126D0 (en)	1996-08-01	1996-08-01	Substituted pyridines as selective cyclooxygenase-2 inhibitors
US2713996P	1996-10-01	1996-10-01
GBGB9621420.0A GB9621420D0 (en)	1996-10-15	1996-10-15	Substituted pyridines as selective cyclooxygenase-2 inhibitors
US4181497P	1997-04-08	1997-04-08
GBGB9709291.0A GB9709291D0 (en)	1997-05-07	1997-05-07	Substituted pyridines as selective cyclooxygenase-2 inhibitors

Publications (1)

Publication Number	Publication Date
DZ2268A1 true DZ2268A1 (fr)	2002-12-25

Family

ID=27547268

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ970118A DZ2268A1 (fr)	1996-07-18	1997-07-16	Pyridines substituées comme inhibiteurs sélectifs de 2-cycloxygènase.

Country Status (37)

Country	Link
EP (1)	EP0912518B1 (fr)
JP (2)	JP3251945B2 (fr)
KR (1)	KR100371620B1 (fr)
CN (1)	CN1152863C (fr)
AR (1)	AR012825A1 (fr)
AT (1)	ATE249437T1 (fr)
AU (1)	AU723179B2 (fr)
BG (1)	BG64553B1 (fr)
BR (1)	BRPI9710372B8 (fr)
CA (2)	CA2412968C (fr)
CO (1)	CO4900063A1 (fr)
CY (1)	CY2409B1 (fr)
CZ (1)	CZ292843B6 (fr)
DE (1)	DE69724788T2 (fr)
DK (1)	DK0912518T3 (fr)
DZ (1)	DZ2268A1 (fr)
EA (1)	EA001444B1 (fr)
EE (1)	EE03680B1 (fr)
ES (1)	ES2205242T3 (fr)
HK (1)	HK1023767A1 (fr)
HR (1)	HRP970389B1 (fr)
HU (1)	HU227732B1 (fr)
ID (1)	ID19602A (fr)
IL (1)	IL127441A (fr)
IS (1)	IS1958B (fr)
MY (1)	MY134841A (fr)
NO (1)	NO313327B1 (fr)
NZ (1)	NZ333230A (fr)
PE (1)	PE27299A1 (fr)
PL (1)	PL187848B1 (fr)
PT (1)	PT912518E (fr)
RS (1)	RS49881B (fr)
SI (1)	SI0912518T1 (fr)
SK (1)	SK283261B6 (fr)
TR (1)	TR199900046T2 (fr)
TW (1)	TW453994B (fr)
WO (1)	WO1998003484A1 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6512121B2 (en)	1998-09-14	2003-01-28	G.D. Searle & Co.	Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6096753A (en) *	1996-12-05	2000-08-01	Amgen Inc.	Substituted pyrimidinone and pyridone compounds and methods of use
JP2001514669A (ja) *	1997-03-14	2001-09-11	メルクフロストカナダアンドカンパニー	シクロオキシゲナーゼ−２阻害薬としてのピリダジノン類
US6004960A (en) *	1997-03-14	1999-12-21	Merck Frosst Canada, Inc.	Pyridazinones as inhibitors of cyclooxygenase-2
US6130334A (en) *	1998-04-15	2000-10-10	Merck & Co., Inc.	Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6127545A (en) *	1997-04-18	2000-10-03	Merck & Co., Inc.	Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
TW492959B (en) *	1997-04-18	2002-07-01	Merck & Co Inc	Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors
JP2001526263A (ja) *	1997-12-19	2001-12-18	アムジエン・インコーポレーテツド	置換ピリジン及びピリダジン化合物並びにそれらの医薬的使用
AR017219A1 (es)	1997-12-19	2001-08-22	Smithkline Beecham Corp	Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
US6174901B1 (en) *	1998-12-18	2001-01-16	Amgen Inc.	Substituted pyridine and pyridazine compounds and methods of use
WO1999045913A1 (fr) *	1998-03-13	1999-09-16	Merck & Co., Inc.	Therapie associee destinee au syndrome ischemique coronarien aigu ainsi qu'a des troubles connexes
US6136804A (en)	1998-03-13	2000-10-24	Merck & Co., Inc.	Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
IL139127A0 (en) *	1998-04-24	2001-11-25	Merck & Co Inc	Process for synthesizing cox -2 inhibitors
US6858617B2 (en)	1998-05-26	2005-02-22	Smithkline Beecham Corporation	Substituted imidazole compounds
WO2000012093A1 (fr) *	1998-08-31	2000-03-09	Merck & Co., Inc.	Procede de traitement des maladies neurodegeneratives
JP2002528506A (ja)	1998-11-04	2002-09-03	スミスクライン・ビーチャム・コーポレイション	ピリジン−４−イルまたはピリミジン−４−イル置換ピラジン
US6350744B1 (en) *	1998-11-20	2002-02-26	Merck & Co., Inc.	Compounds having cytokine inhibitory activity
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AU2408300A (en)	1999-01-08	2000-07-24	Smithkline Beecham Corporation	Novel compounds
MXPA01007169A (es)	1999-01-14	2003-06-06	Lonza Ag	1-(6-metilpiridin-3-il)-2-(4-(metilsulfonil)fenil)etanona y metodo para su elaboracion.
CA2359958C (fr) *	1999-01-14	2006-04-04	Lonza Ag	Procede de preparation de 1-(6- methylpyridin-3-yl)-2-[4-(methylsulfonyl) phenyl]ethanone
US6566527B1 (en)	1999-07-27	2003-05-20	Merck & Co., Inc.	Process for preparing 1-(6-methylpyridin-3-yl)-2-[4-methylsulphonyl)-phenyl]ethanone
EP1233950B1 (fr)	1999-11-23	2005-10-05	Smithkline Beecham Corporation	3,4-dihydro-(1h)quinazolin-2-ones comme inhibiteurs de csbp/p38 kinase
EP1233951B1 (fr)	1999-11-23	2005-06-01	SmithKline Beecham Corporation	Composes de 3,4-dihydro-(1h)quinazolin-2-one utilises comme inhibiteurs de kinase csbp/p38
US6759410B1 (en)	1999-11-23	2004-07-06	Smithline Beecham Corporation	3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
GB9927844D0 (en)	1999-11-26	2000-01-26	Glaxo Group Ltd	Chemical compounds
EP1248618B1 (fr)	1999-11-29	2006-03-22	Merck Frosst Canada Inc.	Formes polymorphes, amorphes et hydratees de 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- 2,3']bipyridinyle
US6858631B1 (en)	1999-11-29	2005-02-22	Merck & Co., Inc.	Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
GB0003224D0 (en) *	2000-02-11	2000-04-05	Glaxo Group Ltd	Chemical compounds
US6521642B2 (en)	2000-05-26	2003-02-18	Merck & Co., Inc.	5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
PH12001001175B1 (en) *	2000-05-26	2006-08-10	Merck Sharp & Dohme	5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
RU2003100874A (ru)	2000-06-13	2004-06-27	Вайс (Us)	Болеутоляющие и противовоспалительные составы, содержащие ингибиторы циклооксигеназы-2
GB0021494D0 (en)	2000-09-01	2000-10-18	Glaxo Group Ltd	Chemical comkpounds
CA2433623A1 (fr) *	2001-01-02	2002-07-18	Fujisawa Pharmaceutical Co., Ltd.	Derives de pyridine utiles en tant qu'inhibiteurs de cyclo-oxygenase
US6673818B2 (en)	2001-04-20	2004-01-06	Pharmacia Corporation	Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
GB0112810D0 (en)	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
GB0112803D0 (en) *	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
GB0112802D0 (en) *	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
DE10129320A1 (de)	2001-06-19	2003-04-10	Norbert Mueller	Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
GB0119477D0 (en)	2001-08-09	2001-10-03	Glaxo Group Ltd	Pyrimidine derivatives
EP1492784A4 (fr)	2002-03-28	2006-03-29	Merck & Co Inc	2,3-diphenyl-pyridines substituees
US7235560B2 (en)	2002-08-19	2007-06-26	Glaxo Group Limited	Pyrimidine derivative as selective COX-2 inhibitors
UY27939A1 (es)	2002-08-21	2004-03-31	Glaxo Group Ltd	Compuestos
EP2305664A1 (fr)	2002-08-30	2011-04-06	Memory Pharmaceuticals Corporation	Dérivés d'anabaseine utiles pour le traitement de maladies neurodégéneratives
GB0221443D0 (en)	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
ATE465725T1 (de)	2002-12-13	2010-05-15	Warner Lambert Co	Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
ES2214130B1 (es) *	2003-02-13	2005-12-01	Almirall Prodesfarma, S.A.	2-3'-bipiridinas.
ES2213485B1 (es)	2003-02-13	2005-12-16	Almirall Prodesfarma, S.A.	Derivados de la 2-fenilpiran-4-ona.
DK1534305T3 (da)	2003-05-07	2007-02-05	Osteologix As	Behandling af brusk-/knoglelidelser med vandoplöselige strontiumsalte
DE10322844A1 (de) *	2003-05-19	2004-12-16	Clariant Gmbh	Verfahren zur Herstellung von Pyridin-2-boronsäureestern
WO2006066968A1 (fr)	2004-12-23	2006-06-29	Glaxo Group Limited	Composes de pyridine destines au traitement de maladies a mediation par prostaglandine
JP2006306743A (ja) *	2005-04-26	2006-11-09	Hamamatsu Photonics Kk	体液処理方法
CA2763671A1 (fr)	2005-04-26	2006-11-02	Pfizer Inc.	Anticorps de la p-cadherine
ES2546069T3 (es)	2005-09-07	2015-09-18	Amgen Fremont Inc.	Anticuerpos monoclonales humanos para quinasa-1 de tipo receptor de activina (ALK-1)
MX2009006575A (es)	2006-12-22	2009-07-02	Recordati Ireland Ltd	Terapia de combinacion de trastornos del tracto urinario inferior con ligandos a2d y farmacos anti-inflamatorios no esteroidales (nsaids).
GB0704407D0 (en)	2007-03-07	2007-04-18	Glaxo Group Ltd	Compounds
US7943658B2 (en)	2007-07-23	2011-05-17	Bristol-Myers Squibb Company	Indole indane amide compounds useful as CB2 agonists and method
GB0813142D0 (en)	2008-07-17	2008-08-27	Glaxo Group Ltd	Novel compounds
GB0813144D0 (en)	2008-07-17	2008-08-27	Glaxo Group Ltd	Novel compounds
EP2177215A1 (fr)	2008-10-17	2010-04-21	Laboratorios Del. Dr. Esteve, S.A.	Co-cristaux de tramadol et NSAID
EP2479166B1 (fr)	2009-02-27	2014-08-20	Cadila Healthcare Limited	Procédé de préparation d'étoricoxib
GB0903493D0 (en)	2009-02-27	2009-04-08	Vantia Ltd	New compounds
WO2011012622A1 (fr)	2009-07-30	2011-02-03	Glaxo Group Limited	Dérivés de benzoxazinone pour traiter des troubles induits par glytl
WO2011023753A1 (fr)	2009-08-27	2011-03-03	Glaxo Group Limited	Dérivés de benzoxazine inhibiteurs du transport de glycine
GB201000685D0 (en)	2010-01-15	2010-03-03	Glaxo Group Ltd	Novel compounds
GB201007791D0 (en)	2010-05-10	2010-06-23	Glaxo Group Ltd	Novel compounds
GB201007789D0 (en)	2010-05-10	2010-06-23	Glaxo Group Ltd	Novel Compound
WO2012004677A1 (fr) *	2010-07-05	2012-01-12	Actavis Group Ptc Ehf	Formes à l'état solide de sels d'étoricoxib
JP5815029B2 (ja)	2010-07-09	2015-11-17	クオンベルゲンセプハルマセウトイカルスリミテッド	カルシウムチャネル遮断薬としてのテトラゾール化合物
US8933132B2 (en)	2011-01-19	2015-01-13	Convergence Pharmaceuticals Limited	Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers
PL2714676T3 (pl)	2011-05-27	2019-10-31	Farma Grs D O O	Sposób wytwarzania formy polimorficznej I etorykoksybu
CN102952117B (zh) *	2011-08-25	2014-11-26	青岛欧博方医药科技有限公司	咪唑衍生物的制备方法
WO2013075732A1 (fr)	2011-11-21	2013-05-30	Synthon Bv	Procédé de préparation d'une forme cristalline i de l'étoricoxib
TW201326154A (zh)	2011-11-28	2013-07-01	拜耳知識產權公司	作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
EP2601952A1 (fr)	2011-12-07	2013-06-12	Zentiva, k.s.	Nouveaux sels et cocrristaux pharmaceutiqement acceptables du 5- chloro-3-(4-méthanesulfonylphényl)-6'-méthyl-[2,3'] bipyridinyle et leurs utilisations thérapeutiques
GB201122113D0 (en)	2011-12-22	2012-02-01	Convergence Pharmaceuticals	Novel compounds
CN103204803A (zh)	2012-01-13	2013-07-17	阿尔弗雷德·E·蒂芬巴赫尔有限责任两合公司	用于合成依托考昔的方法
WO2015036550A1 (fr)	2013-09-13	2015-03-19	Synthon B.V.	Procédé pour la préparation d'étoricoxib
CN104788362A (zh) *	2014-01-21	2015-07-22	济南三元化工有限公司	一种依托考昔或其药学上可接受的盐的制备方法
GB201417497D0 (en)	2014-10-03	2014-11-19	Convergence Pharmaceuticals	Novel use
GB201417500D0 (en)	2014-10-03	2014-11-19	Convergence Pharmaceuticals	Novel use
GB201417499D0 (en)	2014-10-03	2014-11-19	Convergence Pharmaceuticals	Novel use
EP3268085A4 (fr)	2015-03-13	2018-10-31	The Board of Trustees of The Leland Stanford Junior University	Inhibition de ltb4 pour prévenir et traiter le lymphoedème humain
CN106632003B (zh) *	2015-12-31	2019-02-12	上海博志研新药物技术有限公司	一种依托考昔的制备方法
CN106632002A (zh) *	2016-09-28	2017-05-10	贵州大学	一种依托考昔及其对照品5‑氯‑3‑(4‑(甲基磺酰基)苯基)‑2,3‑联吡啶的制备工艺
CN107056781A (zh) *	2017-05-18	2017-08-18	康化（上海）新药研发有限公司	一种(E)‑5‑甲基‑1H‑吡咯并[2,3‑b]吡啶‑3‑甲醛肟的合成方法
CN107286085B (zh) *	2017-05-25	2020-06-16	华东师范大学	一种吡啶类衍生物及其合成方法
CN107556232A (zh) *	2017-09-26	2018-01-09	江苏正大清江制药有限公司	一种依托考昔与盐酸形成盐的新晶型及制备方法
CA3074989A1 (fr) *	2017-10-04	2019-04-11	Japan Tobacco Inc.	Compose heteroaryle contenant de l'azote, et son utilisation pharmaceutique
CN110041253B (zh) *	2018-01-17	2022-03-29	上海翰森生物医药科技有限公司	吡啶类n-氧化衍生物及其制备方法和应用
KR102257685B1 (ko) *	2018-09-20	2021-05-31	성균관대학교산학협력단	Cox-2 억제제를 유효성분으로 포함하는 소염진통 예방 또는 치료용 정제 조성물
CN109432409A (zh) *	2018-12-19	2019-03-08	上海康孕企业管理合伙企业（有限合伙）	血红素在改善痛经的药物、食品及保健食品中的应用
WO2022195579A1 (fr)	2021-03-15	2022-09-22	Saul Yedgar	Dipalmitoyl-phosphatidyl-éthanol-amine conjuguée à l'acide hyaluronique en combinaison avec des médicaments anti-inflammatoires non stéroïdiens (ains) pour traiter ou soulager des maladies inflammatoires
CN115806521A (zh) *	2021-09-15	2023-03-17	华东理工大学	一种单氟甲基依托昔布及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5593994A (en) *	1994-09-29	1997-01-14	The Dupont Merck Pharmaceutical Company	Prostaglandin synthase inhibitors
US5739166A (en) *	1994-11-29	1998-04-14	G.D. Searle & Co.	Substituted terphenyl compounds for the treatment of inflammation
US5686470A (en) *	1995-02-10	1997-11-11	Weier; Richard M.	2, 3-substituted pyridines for the treatment of inflammation

1997
- 1997-07-08 NZ NZ333230A patent/NZ333230A/xx not_active IP Right Cessation
- 1997-07-08 AT AT97929067T patent/ATE249437T1/de active
- 1997-07-08 BR BRPI9710372A patent/BRPI9710372B8/pt not_active IP Right Cessation
- 1997-07-08 CN CNB971963770A patent/CN1152863C/zh not_active Expired - Lifetime
- 1997-07-08 CA CA2412968A patent/CA2412968C/fr not_active Expired - Lifetime
- 1997-07-08 HU HU9903974A patent/HU227732B1/hu unknown
- 1997-07-08 TR TR1999/00046T patent/TR199900046T2/xx unknown
- 1997-07-08 EA EA199900137A patent/EA001444B1/ru not_active IP Right Cessation
- 1997-07-08 DE DE69724788T patent/DE69724788T2/de not_active Expired - Lifetime
- 1997-07-08 CZ CZ1999130A patent/CZ292843B6/cs not_active IP Right Cessation
- 1997-07-08 KR KR10-1999-7000340A patent/KR100371620B1/ko active Protection Beyond IP Right Term
- 1997-07-08 EP EP97929067A patent/EP0912518B1/fr not_active Expired - Lifetime
- 1997-07-08 PT PT97929067T patent/PT912518E/pt unknown
- 1997-07-08 RS YUP-591/98A patent/RS49881B/sr unknown
- 1997-07-08 DK DK97929067T patent/DK0912518T3/da active
- 1997-07-08 WO PCT/CA1997/000486 patent/WO1998003484A1/fr active IP Right Grant
- 1997-07-08 ES ES97929067T patent/ES2205242T3/es not_active Expired - Lifetime
- 1997-07-08 CA CA002260016A patent/CA2260016C/fr not_active Expired - Lifetime
- 1997-07-08 IL IL12744197A patent/IL127441A/xx not_active IP Right Cessation
- 1997-07-08 JP JP50639798A patent/JP3251945B2/ja not_active Expired - Lifetime
- 1997-07-08 AU AU33319/97A patent/AU723179B2/en not_active Expired
- 1997-07-08 EE EEP199900018A patent/EE03680B1/xx unknown
- 1997-07-08 PL PL97330995A patent/PL187848B1/pl unknown
- 1997-07-08 SI SI9730582T patent/SI0912518T1/xx unknown
- 1997-07-08 SK SK36-99A patent/SK283261B6/sk not_active IP Right Cessation
- 1997-07-09 MY MYPI97003127A patent/MY134841A/en unknown
- 1997-07-14 PE PE1997000622A patent/PE27299A1/es not_active IP Right Cessation
- 1997-07-15 TW TW086110013A patent/TW453994B/zh not_active IP Right Cessation
- 1997-07-16 ID IDP972460A patent/ID19602A/id unknown
- 1997-07-16 CO CO97040188A patent/CO4900063A1/es unknown
- 1997-07-16 DZ DZ970118A patent/DZ2268A1/fr active
- 1997-07-17 AR ARP970103217A patent/AR012825A1/es active IP Right Grant
- 1997-07-17 HR HR970389A patent/HRP970389B1/xx not_active IP Right Cessation
1998
- 1998-12-18 IS IS4927A patent/IS1958B/is unknown
1999
- 1999-01-15 NO NO990191A patent/NO313327B1/no not_active IP Right Cessation
- 1999-02-16 BG BG103179A patent/BG64553B1/bg unknown
- 1999-12-09 HK HK99105780A patent/HK1023767A1/xx not_active IP Right Cessation
2001
- 2001-07-10 JP JP2001209904A patent/JP4246930B2/ja not_active Expired - Lifetime
2004
- 2004-03-31 CY CY0400025A patent/CY2409B1/xx unknown

Also Published As

Publication number	Publication date
CA2260016C (fr)	2004-03-09
IS4927A (is)	1998-12-18
PL187848B1 (pl)	2004-10-29
CA2412968C (fr)	2010-05-11
CZ13099A3 (cs)	1999-06-16
EA199900137A1 (ru)	1999-06-24
BG64553B1 (bg)	2005-07-29
IS1958B (is)	2004-11-15
RS49881B (sr)	2008-08-07
AU3331997A (en)	1998-02-10
PT912518E (pt)	2003-12-31
PE27299A1 (es)	1999-03-12
NZ333230A (en)	2000-08-25
CO4900063A1 (es)	2000-03-27
HRP970389A2 (en)	1998-06-30
CA2260016A1 (fr)	1998-01-29
JP3251945B2 (ja)	2002-01-28
MY134841A (en)	2007-12-31
HUP9903974A2 (hu)	2000-03-28
NO990191D0 (no)	1999-01-15
DE69724788D1 (en)	2003-10-16
EP0912518B1 (fr)	2003-09-10
DE69724788T2 (de)	2004-08-05
CZ292843B6 (cs)	2003-12-17
BRPI9710372B8 (pt)	2021-05-25
DK0912518T3 (da)	2003-12-08
EP0912518A1 (fr)	1999-05-06
KR100371620B1 (ko)	2003-05-09
SI0912518T1 (en)	2003-12-31
ID19602A (id)	1998-07-23
JP4246930B2 (ja)	2009-04-02
CY2409B1 (en)	2004-09-10
AR012825A1 (es)	2000-11-22
ATE249437T1 (de)	2003-09-15
HUP9903974A3 (en)	2001-12-28
SK283261B6 (sk)	2003-04-01
BR9710372A (pt)	1999-08-17
HK1023767A1 (en)	2000-09-22
JP2002080453A (ja)	2002-03-19
TW453994B (en)	2001-09-11
NO990191L (no)	1999-03-16
CN1152863C (zh)	2004-06-09
HU227732B1 (en)	2012-01-30
BG103179A (en)	1999-11-30
AU723179B2 (en)	2000-08-17
WO1998003484A1 (fr)	1998-01-29
EE03680B1 (et)	2002-04-15
IL127441A (en)	2003-02-12
JPH11514008A (ja)	1999-11-30
IL127441A0 (en)	1999-10-28
PL330995A1 (en)	1999-06-21
SK3699A3 (en)	1999-12-10
ES2205242T3 (es)	2004-05-01
YU59198A (sh)	2001-07-10
TR199900046T2 (xx)	1999-04-21
CA2412968A1 (fr)	1998-01-29
BR9710372B1 (pt)	2013-02-05
HRP970389B1 (en)	2002-10-31
CN1225085A (zh)	1999-08-04
NO313327B1 (no)	2002-09-16
KR20000067891A (ko)	2000-11-25
EA001444B1 (ru)	2001-04-23
EE9900018A (et)	1999-08-16

Publication	Publication Date	Title
DZ2268A1 (fr)	2002-12-25	Pyridines substituées comme inhibiteurs sélectifs de 2-cycloxygènase.
DZ2261A1 (fr)	2002-12-18	Cyclo-alcane pyridines.
PT901474E (pt)	2006-07-31	Derivados de aril-pirimidina.
PT1114033E (pt)	2004-12-31	4-carboxiamino-2-metil-1,2,3,4-tetra-hidroquinolinas como inibidores de cetp
CU23082A3 (es)	2005-08-17	4-carboxiamino-2-subsituidos-1,2,3,4- tetrahidroquinolas como inhibidores cetp
NO20052407D0 (no)	2005-05-13	Barberhovelhandtak.
ID17659A (id)	1998-01-15	Piridin campuran-bisiklik
PT922050E (pt)	2003-12-31	Derivados de 3-descladinose-2,3-anidroeritromicina
TR199700994A3 (tr)	1998-04-21	Senkronizasyon düzeni.
EE04494B1 (et)	2005-06-15	1-oksa-, asa- ja tianaftaleen-2-oon biseetrid fosfolambaani inhibiitoritena
ES1036598Y (es)	1998-03-01	Capazo-cuna.
TR199700071A2 (tr)	1997-08-21	Tetrahidroizokinolin türevleri.
ES1033200Y (es)	1997-01-01	Linterna - caramelo.
ZA976335B (en)	1998-03-18	Substituted pyridines as selective cyclooxygenase-2 inhibitors.
ES1037689Y (es)	1998-11-01	Bloque aislante perfeccionado.
DZ1864A1 (fr)	2002-02-17	4-Aza-5alpha-cholestan-ones substituées en 7beta comme inhibiteaurs selectifs de 5alpha-reductase.
ES1035219Y (es)	1997-08-01	Chincheta-clip.
ES1033500Y (es)	1997-02-01	Caja-expositor.
KR970052678U (ko)	1997-09-08	피리리드
FI963062A0 (fi)	1996-08-02	Dubbelblad foer stoetblad, skopa, schaktblad
TR199700927A3 (tr)	1999-03-22	N-Benzilazolyum türevleri.
FI962118A0 (fi)	1996-05-20	Foerbaettrad anordning foer behandling av roekgaser, saerskilt avgaser
ITNA960027V0 (it)	1996-04-04	Eritropoietina biotinilata.
DK1062102T3 (da)	2003-03-24	Fremgangsmåde til bogindbinding
GB9616126D0 (en)	1996-09-11	Substituted pyridines as selective cyclooxygenase-2 inhibitors